A new original approach to the design of anticancer drugs based on energy-rich quadricyclanes


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Quadricyclane derivatives are shown for the first time to be promising for application as anticancer drugs. The efficiency of such cage compounds is mainly due to thermal action on cancer cells resulting from a C—C bond cleavage in quadricyclane on exposure to catalytic amounts of cisplatin Pt ions.

作者简介

U. Dzhemilev

Institute of Petroleum Chemistry and Catalysis, Russian Academy of Sciences

Email: tuktarovar@gmail.com
俄罗斯联邦, 141 prosp. Oktyabrya, Ufa, Republic of Bashkortostan, 450075

A. Akhmetov

Institute of Petroleum Chemistry and Catalysis, Russian Academy of Sciences

Email: tuktarovar@gmail.com
俄罗斯联邦, 141 prosp. Oktyabrya, Ufa, Republic of Bashkortostan, 450075

A. Khuzin

Institute of Petroleum Chemistry and Catalysis, Russian Academy of Sciences

Email: tuktarovar@gmail.com
俄罗斯联邦, 141 prosp. Oktyabrya, Ufa, Republic of Bashkortostan, 450075

V. D’yakonov

Institute of Petroleum Chemistry and Catalysis, Russian Academy of Sciences

Email: tuktarovar@gmail.com
俄罗斯联邦, 141 prosp. Oktyabrya, Ufa, Republic of Bashkortostan, 450075

L. Dzhemileva

Institute of Petroleum Chemistry and Catalysis, Russian Academy of Sciences

Email: tuktarovar@gmail.com
俄罗斯联邦, 141 prosp. Oktyabrya, Ufa, Republic of Bashkortostan, 450075

M. Yunusbaeva

Institute of Petroleum Chemistry and Catalysis, Russian Academy of Sciences

Email: tuktarovar@gmail.com
俄罗斯联邦, 141 prosp. Oktyabrya, Ufa, Republic of Bashkortostan, 450075

L. Khalilov

Institute of Petroleum Chemistry and Catalysis, Russian Academy of Sciences

Email: tuktarovar@gmail.com
俄罗斯联邦, 141 prosp. Oktyabrya, Ufa, Republic of Bashkortostan, 450075

A. Tuktarov

Institute of Petroleum Chemistry and Catalysis, Russian Academy of Sciences

编辑信件的主要联系方式.
Email: tuktarovar@gmail.com
俄罗斯联邦, 141 prosp. Oktyabrya, Ufa, Republic of Bashkortostan, 450075

补充文件

附件文件
动作
1. JATS XML

版权所有 © Springer Science+Business Media, LLC, part of Springer Nature, 2019